Molecular Subtyping Genomic Test Better for Breast Cancer, Agendia Study Says

Molecular Subtyping Genomic Test Better for Breast Cancer, Agendia Study Says
dan breast cancer sub typingA surgical oncologist from Nashville and his team of fellow researchers recently published an observational study that compares two types of presurgical assessment tests for breast cancer patients. One of them was discovered to yield more accurate results, potentially allowing oncologists to prescribe a more effective treatment plan. Dr. Pat Whitworth, the study's lead author, focused the team's attention on the BluePrint genomic test and the traditional IHC-FISH pathology tests. 426 breast cancer patients participated in the research, which revealed the genomic test gave physicians a more accurate prediction of a patient's response to preoperative therapy as the BluePrint test was more specific with the molecular subtype of breast cancer. The study is currently available online in the Annals of Surgical Oncology, entitled, "A Comparison of Ink-Directed and Traditional Whole-Cavity Re-Excision for Breast Lumpectomy Specimens With Positive Margins." According to the study, the 80-gene BluePrint text was able to properly reclassify roughly 22% of sampled breast tum
Subscribe or to access all post and page content.